MAPT and Alzheimer disease: Recently, the spatiotemporal development of Aβ and Tau-pathology in AD patients has been confirmed by neurofunctional imaging using Positron Emission Tomography (PET), indicating the initial formation of Aβ in the cortex, a part of the brain with high metabolic demand, and the spreading from the neocortex to the brainstem, and the cerebellum finally [43,44].